During chronic kidney disease (CKD), Epo‐deficiency anaemia is commonly observed and needs to be treated by recombinant Epo injections or, more recently, by oral application of hypoxia‐inducible factor (HIF) stabilizers.16 This evidence concerns the gene EPO and anemia (phenotype).